Here's What Key Metrics Tell Us About Koppers (KOP) Q3 Earnings

Koppers (KOP) reported $485.3 million in revenue for the quarter ended September 2025, representing a year-over-year decline of 12.5%. EPS of $1.21 for the same period compares to $1.37 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $514.57 million, representing a surprise of -5.69%. The company delivered an EPS surprise of -3.2%, with the consensus EPS estimate being $1.25.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Koppers performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Net Sales- Carbon Materials & Chemicals: $108.3 million versus $115.6 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -16.4% change.Net Sales- Performance Chemicals: $144.3 million versus $148.6 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -18.3% change.Net Sales- Railroad & Utility Products and Services: $232.7 million versus $252.15 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -6.2% change.View all Key Company Metrics for Koppers here>>>Shares of Koppers have returned +5.1% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Koppers Holdings Inc. (KOP): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks